Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib.
Duffy AG, Ulahannan SV, Cao L, Rahma OE, Makarova-Rusher OV, Kleiner DE, Fioravanti S, Walker M, Carey S, Yu Y, Venkatesan AM, Turkbey B, Choyke P, Trepel J, Bollen KC, Steinberg SM, Figg WD, Greten TF. Duffy AG, et al. Among authors: makarova rusher ov. United European Gastroenterol J. 2015 Oct;3(5):453-61. doi: 10.1177/2050640615583587. United European Gastroenterol J. 2015. PMID: 26535124 Free PMC article.
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.
Duffy AG, Ma C, Ulahannan SV, Rahma OE, Makarova-Rusher O, Cao L, Yu Y, Kleiner DE, Trepel J, Lee MJ, Tomita Y, Steinberg SM, Heller T, Turkbey B, Choyke PL, Peer CJ, Figg WD, Wood BJ, Greten TF. Duffy AG, et al. Clin Cancer Res. 2017 Aug 15;23(16):4633-4641. doi: 10.1158/1078-0432.CCR-16-3171. Epub 2017 May 2. Clin Cancer Res. 2017. PMID: 28465443 Free PMC article. Clinical Trial.
Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.
Duffy AG, Makarova-Rusher OV, Ulahannan SV, Rahma OE, Fioravanti S, Walker M, Abdullah S, Raffeld M, Anderson V, Abi-Jaoudeh N, Levy E, Wood BJ, Lee S, Tomita Y, Trepel JB, Steinberg SM, Revenko AS, MacLeod AR, Peer CJ, Figg WD, Greten TF. Duffy AG, et al. Among authors: makarova rusher ov. Int J Cancer. 2016 Oct 1;139(7):1648-57. doi: 10.1002/ijc.30199. Epub 2016 Jun 27. Int J Cancer. 2016. PMID: 27194579 Free PMC article. Clinical Trial.
The yin and yang of evasion and immune activation in HCC.
Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. Makarova-Rusher OV, et al. J Hepatol. 2015 Jun;62(6):1420-9. doi: 10.1016/j.jhep.2015.02.038. Epub 2015 Feb 27. J Hepatol. 2015. PMID: 25733155 Free article. Review.
The case for immune-based approaches in biliary tract carcinoma.
Duffy AG, Makarova-Rusher OV, Greten TF. Duffy AG, et al. Among authors: makarova rusher ov. Hepatology. 2016 Nov;64(5):1785-1791. doi: 10.1002/hep.28635. Epub 2016 Jun 18. Hepatology. 2016. PMID: 27177447 Free PMC article. Review.
Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.
Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Gupta N, Johung KL, Klopp A, LaCasce AS, Lin C, Makarova-Rusher OV, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A, Palella F, Ratner L, Rizza S, Rudek MA, Taylor J, Tomlinson B, Wang CJ, Dwyer MA, Freedman-Cass DA. Reid E, et al. Among authors: makarova rusher ov. J Natl Compr Canc Netw. 2018 Aug;16(8):986-1017. doi: 10.6004/jnccn.2018.0066. J Natl Compr Canc Netw. 2018. PMID: 30099375